In a new GARDP antimicrobial viewpoint piece, Jon Iredell and Jessica Sacher of Phage Australia discuss ways to improve the economics of personalized phage therapy as part of a clinical service, including increasing the number of patients who benefit from each phage batch, establishing safety through endpoint rather than full process controls, and exploring new payment models like value-based pricing.